Skip to main content

Table 2 Baseline characteristics of PS-matched patients with and without inhibitors in the CHESS studya

From: Inhibitor clinical burden of disease: a comparative analysis of the CHESS data

Characteristic Patients who never developed inhibitors Patients with current inhibitors p-valueb
N = 58 N = 58
Demographics
 Age, years
  Mean ± SD 43.71 ± 17.17 41.90 ± 14.95 .4800
  Median (range) 43 (18.00–88.00) 39.5 (18.00–80.00)  
 Race, N (%)
  White 43 (74.1) 49 (84.5) .1573
 Body mass index
  Mean ± SD 24.92 ± 2.67 25.31 ± 2.78 .4072
  Median (range) 25.08 (15.57–32.02) 25.00 (20.52–32.83)  
Hemophilia type, N (%)
 Hemophilia A 47 (81.0) 47 (81.0) 1.0000
Comorbidities, N (%)
 Alcohol dependence 7 (12.1) 4 (6.9) .3173
 Anemia 6 (10.3) 8 (13.8) .5271
 Anxiety 13 (22.4) 12 (20.7) .8415
 Depression 13 (22.4) 11 (19.0) .6374
 Diabetes mellitus 7 (12.1) 8 (13.8) .7389
 Fibromyalgia 3 (5.2) 7 (12.1) .1573
 Hepatitis B virus 1 (1.7) 1 (1.7) 1.0000
 Hepatitis C virus 9 (15.5) 5 (8.6) .2850
 Human immunodeficiency virus 8 (13.8) 3 (5.2) .0956
 Hypertension 15 (25.9) 13 (22.4) .6374
 Hypercholesterolemia 7 (12.1) 5 (8.6) .5271
 Ischemic heart disease 4 (6.9) 3 (5.2) .7055
 Obesity 1 (1.7) 3 (5.2) .3173
 Osteoarthritis 7 (12.1) 8 (13.8) .7815
  1. Abbreviations: BMI body mass index, CHESS Cost of Haemophilia across Europe – a Socioeconomic Survey, PS propensity score, SD standard deviation
  2. aPatients with current inhibitors were matched to patients who had never developed an inhibitor based on demographics (age, BMI, race) and comorbidity status using propensity scores stratified by hemophilia type. Matching was performed using a preset caliper size of 0.035 to maintain the maximum sample size using the smallest caliper width
  3. bP-values were derived from a paired t-test or Wilcoxon signed rank test for continuous post-match variables and the McNemar’s test or exact McNemar’s test for categorical variables; p < .05 indicates statistical significance